Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 54 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• AK105 Combined With Anlotinib in Patients With Cervical CancerActive, not recruitingNCT05137171Phase 2
• Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)Status unknownNCT05136768Phase 2
• A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2
• Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
• HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureStatus unknownNCT05135364Phase 2
• A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsCompletedNCT05134948Phase 1/2
• Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal CancersActive, not recruitingNCT05131919Phase 2
• Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1
• Neo-NTP-CRT for Locally Advanced ESCCStatus unknownNCT05130684Phase 2
• Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaActive, not recruitingNCT05130177Phase 2
• Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral SuppressionStatus unknownNCT05129189Phase 2
• A Study Explore JS001+JS002 in Patients With Advanced CancerTerminatedNCT05128539Phase 1
• Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPiWithdrawnNCT05126342Phase 2
• Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder CancerWithdrawnNCT05120622Phase 1/2
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in ChinaTerminatedNCT05120375Phase 1
• A Phase I Study of IBI325 in Patients With Advanced Solid TumorCompletedNCT05119998Phase 1
• Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for OxaliplatinActive, not recruitingNCT05118724Phase 2
• IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedNCT05118334Phase 1
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2
• Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.TerminatedNCT05116917Phase 2
• Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid TumorsCompletedNCT05116709Phase 1
• Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerActive, not recruitingNCT05116462Phase 3
• Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLCCompletedNCT05116007Phase 1
• Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal SinusesStatus unknownNCT05114707Phase 2
• Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer PatientsActive, not recruitingNCT05114421Phase 2
• Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
• Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
• TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After ResectionStatus unknownNCT05111366Phase 2
• Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour PatientsTerminatedNCT05109650Phase 1
• Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular CarcinomaWithdrawnNCT05109052Phase 1/2
• A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCTerminatedNCT05106335Phase 3
• A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical CancerStatus unknownNCT05105672Phase 2
• Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaActive, not recruitingNCT05102721Phase 1/2
• HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid TumorsStatus unknownNCT05102214Phase 1/2
• A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant TumorsCompletedNCT05102006Phase 1/2
• Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based TherapyCompletedNCT05101629Phase 2
• A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric CancerSuspendedNCT05101616Phase 1/2
• A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550CompletedNCT05101369Phase 1
• Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid TumorsCompletedNCT05101109Phase 1
• A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular CarcinomaCompletedNCT05099848Phase 2
• Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.Active, not recruitingNCT05097911Phase 1
• Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors PatientsStatus unknownNCT05097781Phase 2
• Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of ChemotherapyStatus unknownNCT05097248Phase 2
• Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
• Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05095636Phase 2
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerWithdrawnNCT05093387Phase 1
• Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCLStatus unknownNCT05093140Phase 2
• Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCActive, not recruitingNCT05092412Phase 2
• Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05092217Phase 2
• Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung CancerTerminatedNCT05088967Phase 1
• Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerStatus unknownNCT05088057Phase 2
• Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant MelanomaStatus unknownNCT05087602Phase 2
• Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal CancerCompletedNCT05086627Phase 2
• Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
• A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsCompletedNCT05082610Phase 1
• Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
• Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaActive, not recruitingNCT05079282Phase 1
• A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsActive, not recruitingNCT05078931Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or LymphomaCompletedNCT05078593Phase 1
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed GlioblastomaTerminatedNCT05074992Phase 2
• Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor PatientsTerminatedNCT05073484Phase 1
• A Study of Pembrolizumab and Cryoablation in People With MesotheliomaCompletedNCT05071014Phase 1
• Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Phase 2
• Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver MetastasisStatus unknownNCT05070221Phase 1
• Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver MetastasisStatus unknownNCT05068453Phase 1
• Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.CompletedNCT05068427Phase 2
• A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOxStatus unknownNCT05068206Phase 2
• A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownNCT05068141Phase 2
• Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast CancerCompletedNCT05064085Phase 1
• Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixActive, not recruitingNCT05063916Phase 2
• TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedNCT05062980Phase 1
• The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced TumorCompletedNCT05061628Phase 1
• PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA PatientsCompletedNCT05060471Phase 2
• Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingNCT05060432Phase 1/2
• Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingNCT05059522Phase 3
• Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
• Tislelizumab in Addition to BACE in Patients with NSCLCCompletedNCT05058560Phase 2
• Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCStatus unknownNCT05056337Phase 3
• Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLCStatus unknownNCT05055583Phase 2
• Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLCActive, not recruitingNCT05055167Phase 2
• First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid TumorsCompletedNCT05054348Phase 1
• A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeActive, not recruitingNCT05053880Phase 1/2
• Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCCCompletedNCT05053737Phase 1
• Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2
• DCF Combined With Camrelizumab in the Treatment of Esophageal CancerStatus unknownNCT05050760Not applicable
• A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Phase 3
• Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
• Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.Active, not recruitingNCT05043688Phase 3
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal AdenocarcinomaActive, not recruitingNCT05041153Early Phase 1
• A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2
• Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Status unknownNCT05039658Phase 1
• Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyStatus unknownNCT05039580Phase 4
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2

← Immune Checkpoint Inhibitors overview